Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade
BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year ago.
BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial Officer Vincent O'Neill - Executive Vice President, Chief of Product Development and Medical Officer Rob Risinger - Chief Medical Officer, Neuroscience Conference Call Participants Matt Wiley - Senior Vice President and Chief Commercial Officer Frank Yocca - Chief Scientific Officer Operator Good morning, and welcome to the BioXcel Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BioXcel Therapeutics (BTAI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Vincent O'Neill - Executive Vice President, Chief of Product Development and Medical Officer Richard Steinhart - Senior Vice President and Chief Financial Officer Matt Wiley - Senior Vice President and Chief Commercial Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Raghuram Selvaraju - H.C. Wainwright Operator Good morning, and welcome to the BioXcel Therapeutics Second Quarter 2024 Earnings Conference Call.
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $1.83 per share a year ago.
